Pharmamarketeer

Astellas' Xospata gets European approval as monotherapy for patients with relapsed/refractory AML with FLT3 mutation

Astellas Pharma Inc. announced that the European Commission (EC) has approved the oral once─daily therapy Xospata (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory

Medhc-fases-banner
Advertentie(s)